Bold claim: Obamacare subsidy fraud wastes taxpayers’ money and distorts the health market. And this is the part most people miss: the system’s complexity can obscure how subsidies interact with costs, incentives, and oversight.
A joint hearing by the House Judiciary Subcommittee on Oversight and the Subcommittee on the Administrative State, Regulatory Reform, and Antitrust is scheduled for Wednesday, December 10, 2025, at 2:00 p.m. ET in Washington, D.C. The focus is on evaluating whether the Administrative Procedure Act effectively guards against subsidy fraud within Obamacare, including the enhanced COVID-19-era subsidies championed by the Biden-Harris administration that are slated to end after 2025. The discussion will also explore how these subsidies may raise overall health care costs and foster opportunities for waste, fraud, and abuse.
Witnesses:
- Dr. Ge Bai, Professor of Accounting at Johns Hopkins Carey Business School and Professor of Health Policy & Management at Johns Hopkins Bloomberg School of Public Health
- Seto Bagdoyan, Director of Audit Services, Forensic Audits & Investigative Service, Government Accountability Office
- Dr. Brian Blase, President, Paragon Institute of Health
- Zack Cooper, Ph.D., Associate Professor of Public Health and Economics at Yale University
If you’re following the debate over health policy subsidies, this hearing spotlights pivotal questions: Do current procedures deter misuse without stifling legitimate aid? Are enhanced subsidies contributing to higher premiums or other downstream costs? And what accountability mechanisms are truly effective in preventing fraud while ensuring access to care for those who need it most? These are the core tensions that could shape policy choices well into the next decade.
Thought-provoking angles you might consider: should subsidy rules be tightened through more rote administrative checks, or balanced with simpler eligibility standards to reduce gaming opportunities? Could there be smarter targeting of subsidies to low-income households rather than broad-based boosts? And how might reform proposals align incentives so providers focus on value rather than volume? Share your take in the comments: Do the potential savings from tighter controls justify any risk of reduced access or slower program approvals?
